



Gennex Laboratories Limited

'AKASH GANGA' III Floor, Plot No.144 Srinagar Colony, Hyderabad – 500 073, TELANGANA (INDIA)
Tel: +91-40-67334400 (30 lines) / 2374 6451, Fax: 67334433/01,
Email:info@gennexlab.com, www.gennexlab.com

Ref: GLL/Board/2017-18/0008

Date: 30/05/2017.

To
Dy. General Manager,
Bombay Stock Exchange Ltd.,
Phiroje Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001.
Script Code – 531739

To
Asst. Manager (Listing)
The Ahmedabad Stock Exchange Ltd.,
Kamdhenu Complex, Opp.Sahajanand College,
Ahmedabad – 380 015.

To
The Secretary
The Calcutta Stock Exchange Association Ltd.,
7, Lyons Range, Calcutta – 700 001.

Dear Sir/Madam,

Subject : Announcement of Audited financial results for the Year Ended March 31, 2017
together with the Report of Auditors and Annexure – I.

Reference : Reg. 30(2) and Reg.33 of SEBI (LODR) Regulations, 2015.

This is to inform you that the Audited financial results for the year ended March 31, 2017 was approved and taken on records by the Board of Directors at their meeting held on May 30, 2017. The same was signed by Mr. Arihant Baid, Managing Director of the Company. We enclose Audited financial results for year ended March 31, 2017 together with the Report of the Auditors in respect of the Audited Financial results for the year ended March 31, 2017 along with Annexure – I. We are arranging publication of the results in the newspaper and also in the website of the Company as required under Reg.33 read with 47 of SEBI (LODR) Regulations, 2015.

The Meeting commenced at 12.30 P.M. and concluded at 07.15 P.M.

Kindly bring this to the notice of the members of the Exchange.

Thanking You,

Yours faithfully,
For Gennex Laboratories Ltd.,

T.M.Gopalakrishnan
Whole-Time Director

Encl: as above


GENNEX LABORATORIES LIMITED

 REGD. OFF: SURVEY NO. 133, BOLLARAM, JINNARAM MANDAL, MEDAK DIST - 502 325
 Statement of Audited Results for the Quarter and Year Ended 31st March, 2017

PART I		(Rs. in lakhs)				
Sl. No.	Particulars	Quarter Ended			Year Ended	
		31.03.2017	31.12.2016	31.03.2016	31.03.2017	31.03.2016
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	Income from Operations					
	Sales/Income from Operations	1138.57	1125.05	1049.86	4330.64	4031.24
	Less: Excise Duty	30.68	66.91	54.96	157.89	178.03
a	Net Sales/Income from Operations	1107.89	1058.14	994.90	4172.75	3853.21
b	(b) Other operating Income	0.40	0.26	0.39	17.97	2.39
	Total Income from operations (net)	1108.29	1058.40	995.29	4190.72	3855.60
2	Expenses					
	(a) Cost of material consumed	661.75	619.39	630.66	2356.98	2358.37
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	65.78
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-45.60	-3.72	-96.82	35.71	-161.06
	(d) Employee benefit expense	157.24	118.25	118.75	495.88	411.56
	(e) Finance Costs	29.14	7.72	13.85	70.54	50.38
	(f) Depreciation and amortisation expense	22.76	20.60	19.64	83.94	83.60
	(g) Other expenses	269.09	204.54	218.29	849.48	761.28
	Total expenses	1094.38	966.78	904.37	3892.53	3569.91
3	Profit(+)/Loss(-) from operations before other income and exceptional items (1-2)	13.91	91.62	90.92	298.19	285.69
4	Other income	-0.13	6.22	5.09	11.89	21.43
5	Profit(+)/Loss(-) from ordinary activities before exceptional items (3+4)	13.78	97.84	96.01	310.08	307.12
6	Exceptional items	0.00	0	1.15	0	-3.78
7	Profit(+)/Loss(-) from ordinary activities before tax (5+6)	13.78	97.84	97.16	310.08	303.34
8	Tax expense	36.58	-0.85	69.24	39.65	69.65
9	Profit(+)/Loss(-) from ordinary activities after tax (7-8)	-22.80	98.69	27.92	270.43	233.69
10	Extraordinary items (net of tax expense Rs. Lakhs)	0	0	0	0	0
11	Net Profit(+)/Loss(-) for the period (9+10)	-22.80	98.69	27.92	270.43	233.69
12	Paid-up Equity Share Capital (Face value Rs. 1 each Equity Share)	1265.03	1265.03	1265.03	1265.03	1265.03
13	Reserve excluding Revaluation Reserves				1829.09	1558.66
14. i	Earning Per Share (before extraordinary items) (of Rs. 1 each) (not annualised) :					
	(a) Basic	-0.018	0.078	0.022	0.214	0.185
	(b) Diluted	-0.018	0.078	0.022	0.214	0.185
14. ii	Earning Per Share (after extraordinary items) (of Rs. 1 each) (not annualised) :					
	(a) Basic	-0.018	0.078	0.022	0.214	0.185
	(b) Diluted	-0.018	0.078	0.022	0.214	0.185

Standalone Statement of assets and liabilities.

(Rs. In Lakhs)

Particulars	31-03-2017		31-03-2016
A) EQUITY AND LIABILITIES	Audited		Audited
1 Shareholders' Funds:			
a) Share Capital	1265.03		1265.03
b) Reserves and Surplus	1829.09		1558.65
	3094.12		2823.68
2 Non - Current Liabilities			
a) Long-term borrowings			
- Secured	8.55		3.05
- Unsecured	10.01		11.72
b) Deferred Tax Adjustment	94.89		98.31
c) Long-term provisions	0		0
	113.45		113.08
3 Current Liabilities			
a) Short-term borrowings			
- Secured	375.16		223.79
- Unsecured	5.96		4.25
b) Trade payables	967.25		704.65
c) Others current liabilities	315.91		233.88
d) short-term provisions	50.06		75.78
TOTAL	1714.34		1242.35
GRAND TOTAL (1+2+3)	4921.91		4179.11
B) ASSETS			
1 Non-Current Assets			
a) Fixed Assets			
i) Tangible Assets	1574.11		1557.92
ii) Intangible Assets	0.00		0.00
b) Non-Current Investments	701.00		701.00
c) Other non-current assets	22.14		23.97
	2297.25		2282.89
2 Current Assets			
a) Inventories	289.04		294.20
b) trade receivable	1029.56		695.93
c) Cash and Cash equivalents	62.95		84.78
d) Short-term loans and Advances	1242.03		817.38
e) Other current assets	1.08		3.93
TOTAL	2624.66		1896.22
GRAND TOTAL (1+2)	4921.91		4179.11

NOTES:

- 1) The above audited results for the quarter and year ended March 31,2017 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 30, 2017.
- 2) Tax Expenses include Current Tax and Deferred tax.
- 3) The major operations of the company relate to only one segment viz., Bulk Drugs, Biotech Products & Intermediates. As such there is no separate reportable segment under Accounting Standard 17 of Segment Reporting.
- 4) The figures of the current quarter ending on 31st March,2017 are the balancing figures between the Audited figures of the full Financial year ended 31st March,2017 & the published year to date figures upto 3rd Quarter ended December 31st,2016.
- 5) Previous period's figures have been regrouped / rearranged wherever considered necessary.

Place: Hyderabad
Date: 30.05.2017

For and on behalf of the Board
For Gennex Laboratories Limited

sd/-
Arihant Baid
(Managing Director)

Auditor's Report On Quarterly Financial Results and Year to Date Results of M/s Gennex Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015

To
Board of Directors
M/s Gennex Laboratories Limited
Hyderabad

We have audited the quarterly financial results of **M/s Gennex Laboratories Limited** for the quarter ended **31st March 2017** and the year to date results for the period **01st April 2016 to 31st March 2017** attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.


These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly standalone financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the loss and other financial information for the quarter ended 31st March, 2017 as well as the year to date results for the period from 01st April 2016 to 31st March 2017

For Laxminiwas & Jain
Chartered Accountants
Firm Registration no.:001859S


(Sharda G Patil)
Partner

M.No: 015332

Place: Hyderabad
Date:30/05/2017

